Aspirin-Free Strategy for Percutaneous Coronary Intervention in Patients With Oral Anticoagulation: Prespecified Subgroup Analysis From the STOPDAPT-3 Trial.
Masahiro NatsuakiHirotoshi WatanabeTakeshi MorimotoKo YamamotoYuki ObayashiRyusuke NishikawaKenji AndoSatoru SuwaTsuyoshi IsawaHiroyuki TakenakaTetsuya IshikawaMinoru YamadaTetsuzo WakatsukiYoichi NozakiHideki KitaharaRyuichi KatoRyoma KawaiYohei KobayashiMitsuru IshiiYoshitaka GotoKoh OnoTakeshi KimuraPublished in: Journal of the American Heart Association (2024)
The no-aspirin strategy compared with the DAPT strategy failed to reduce major bleeding events irrespective of the use of OAC. There was a numerical excess risk of the no-aspirin strategy relative to the DAPT strategy for cardiovascular events in patients with OAC.
Keyphrases
- cardiovascular events
- antiplatelet therapy
- percutaneous coronary intervention
- coronary artery disease
- low dose
- acute coronary syndrome
- atrial fibrillation
- cardiovascular disease
- clinical trial
- acute myocardial infarction
- st segment elevation myocardial infarction
- coronary artery bypass grafting
- randomized controlled trial
- phase iii
- study protocol
- venous thromboembolism
- st elevation myocardial infarction
- left ventricular
- double blind
- phase ii